Condition: Autoimmune Encephalitis · Encephalitis · Sponsor: University of Utah
Determine the difference in the modified Rankin score at 16 weeks in participants with anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis treated with "first-line" immunomodulatory therapies provided as standard-of-care, and either inebilizumab (investigational agent) or placebo.
This description comes directly from the study's public registry record.
Stacey L Clardy, MD, PhD · 8015857575 · stacey.clardy@hsc.utah.edu
Ka-Ho Wong, MBA · 8015857575 · ka-ho.wong@hsc.utah.edu
Always discuss trial participation with your own doctor first.
| University of Alabama at Birmingham | Birmingham, Alabama, United States | Recruiting |
| St. Joseph Hospital and Medical Center Barrow Neurological Institute | Phoenix, Arizona, United States | Recruiting |
| Mayo Clinic in Arizona | Scottsdale, Arizona, United States | Recruiting |
| Children's Hospital of Orange County | Orange, California, United States | Recruiting |
| UC Irvine | Orange, California, United States | Recruiting |
| UC Davis | Sacramento, California, United States | Recruiting |
| Children's Hospital Colorado Main Campus | Aurora, Colorado, United States | Recruiting |
| University of Colorado | Aurora, Colorado, United States | Recruiting |
| Yale University | New Haven, Connecticut, United States | Recruiting |
| Mayo Clinic Jacksonville | Jacksonville, Florida, United States | Recruiting |
| University of Miami | Miami, Florida, United States | Recruiting |
| Emory University | Atlanta, Georgia, United States | Recruiting |
+ 27 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04372615